Abstract：
We present a case of a 30-year-old man with relapsing-remitting multiple sclerosis who developed psoriasiform dermatitis following his second course of ocrelizumab. This resolved with topical therapies and discontinuation of treatment. Cases of psoriasiform rashes have been increasingly reported in the use of ocrelizumab and are possibly due to B-cell (CD20) depletion and T-cell overregulation. Nevertheless, skin-related adverse reactions are not yet considered in the risk management plans of anti-CD20 treatments in multiple sclerosis.
摘要：
我们介绍了一例30岁的复发缓解型多发性硬化症患者，他在第二个疗程的奥克利珠单抗治疗后出现了银屑病样皮炎。这通过局部治疗和停止治疗解决。在使用ocrelizumab时，越来越多地报道了银屑病样皮疹的病例，这可能是由于B细胞（CD20）耗竭和T细胞过度调节所致。然而，多发性硬化症抗CD20治疗的风险管理计划中尚未考虑皮肤相关不良反应.
